


Studier viser vektoppgang etter seponering på Wegovy og Saxenda





Det er flere studier på Wegovy og Saxenda som viser at pasientene går opp vekttapet innen 1 år etter seponering og dette gjelder også for barn, eksempelvis:

“Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. The STEP 4 Randomized Clinical Trial”:



“3 years of liraglutide versus placebo for type 2 diabetes riskreduction and weight management in individuals with prediabetes: a randomized, double-blind trial.”

Forlengelse av STEP 1:



“In conclusion, among adults with overweight/obesity, after a substantial reduction in body weight during 68 weeks of treatment with once-weekly s.c. semaglutide plus lifestyle intervention, subsequent treatment withdrawal led to most of the weight loss being regained within 1 year, and a similar change in some cardiometabolic variables back to baseline, reinforcing the need for continued treatment to maintain weight loss and cardiometabolic benefits.”




Figure 3: Liraglutide 3.0 mg and bodyweight

Data shown are the observed means for the full-analysis set, with LOCF. LOCF=last-observation-carried-forward. OR=odds ratio. *p<0.0001. †Analysis for >15% weight